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OBJECTIVES: Osteosarcoma of the jaw (OSAJ) is fundamentally different in clinical practice from its peripheral
counterparts. Studies are difficult to conduct due to low incidence rates. The primary aim of this study was to
provide for the first time a comprehensive retrospective analysis of the treatment concepts and outcome data of
OSAJ patients treated at the University Hospital Vienna and to compare these with two recently published
studies on OSAJ. The clinical study was accompanied by a biomarker study investigating the prognostic
relevance of melanoma-associated antigen-A (MAGE-A) in OSAJ specimens.
METHOD: Eighteen patients were included, and their outcomes were compared to published data. Immuno-
histochemistry was performed with mouse monoclonal antibodies against MAGE-A. Survival rates were estimated
by the Kaplan-Meyer method. The log-rank test was used to analyze potential prognostic parameters. Fisher’s
exact test was performed to define the significant differences between the survival rates of the current study and
the DOESAK registry.
RESULTS: Disease-specific survival was 93.8% after five and 56.3% after ten years. The development of
metastases (p=0.033) or relapse (p=0.037) was associated with worsened outcomes in our group as well as in
the comparative group. Despite the different treatment concepts of the study groups, survival rates were
comparable. MAGE-A failed to show prognostic relevance for OSAJ patients.
CONCLUSIONS: Uncertainties about the optimal treatment strategies of OSAJ patients will currently remain.
Thus, prospective studies of OSAJ are needed but are only feasible in a multicenter study setting, conducted
over a prolonged time period.
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’ INTRODUCTION
Osteosarcoma (OSA) belongs to the most common primary
malignant tumors of the bone, of which approximately 6-7%
are primarily localized in the jaw bones (1-3). Approximately
5% of OSAs are thought to be secondary malignancies induced
by exposure to ionizing irradiation (4-6). The reported incidence
of radiation-induced OSAs is approximately 0.8% (5).
Unfortunately, comprehensive studies of osteosarcomas
of the jaw (OSAJs) are difficult to conduct due to the low
incidence (2 cases per 10 million). Thus, OSAJs are often
subject to nonuniform treatment modalities. These strategies
are often adapted from the treatment concepts of OSA of the
long bones and craniofacial OSAs (3,7-10). No particular
pathohistological, radiological or immunohistochemical dif-
ferences between OSAJ and OSA of the peripheral bone
(OSAP) have been described until now. However, OSAJ
shows several clinical features distinct from those of OSAP.
For example, patients with OSAJ are, on average, approxi-
mately two decades older, and they tend to have a lower risk
for hematologic dissemination, which is associated with
higher survival rates (3).
The primary aim of this study was to provide for the first
time a comprehensive, retrospective analysis of the treatment
concepts and outcome data of OSAJ patients treated at the
Department of Cranio-, Maxillofacial and Oral Surgery at
the University of Vienna from 1995 until 2015. Additionally,
we sought to compare these results with data published
by Baumhoer et al. (1) from the DOESAK (German-Swiss-
Austrian Workgroup on Maxillofacial Tumors) tumor registry
(https://doesak.med.uni-rostock.de/) and Lee et al. (3) who
published data derived from the SEER (population-based USDOI: 10.6061/clinics/2019/e701
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Surveillance, Epidemiology and End Results) cancer registry.
As the Institute of Pathology at the Medical University of
Vienna serves as a reference center for Austria, no specimens
from our clinic have been deposited at the DOESAK registry.
Furthermore, we conducted an accompanying biomarker
study investigating the expression of the melanoma-
associated antigen-A (MAGE-A) family in OSAJ specimens.
MAGEs, which are recognized by T-cells, are typically not
expressed in normal tissues except for the testis, in which
spermatogonia and spermatocytes are MAGE-A positive
(11). The potential prognostic relevance of MAGE-A was
demonstrated by several investigators (12-18). These pub-
lications showed a correlation of MAGE-A expression and
the potential for the development of distant metastasis in
various tumors. In particular, the expression of MAGE-A1,
A3, A4, A6 and A12 isoforms are of interest because they
were overexpressed in malignancies compared to levels in
healthy tissues (11). Until now, little was known about the
expression, function and potential therapeutic relevance of
the MAGE-A family of proteins in OSA, although it has been
suggested (19) that this antigen might serve as a potential
target for adoptive immunotherapy (19-22). MAGE-A exp-
ression was therefore evaluated to assess a possible correla-
tion with the malignant potential of OSAJs.
’ MATERIALS AND METHODS
Patients
Eligible participant for this retrospective study were
patients who were treated for histopathologically proven
OSAJ. We only included patients with complete documenta-
tion and follow-up. Patients with OSA of the cranial bones or
other primary sites of the viscerocranial bones or OSA of the
external skeleton were excluded. The observation period
encompassed 20 years (1995-2015).
Treatment
As OSAJ is rare and is clinically as well as therapeutically
distinct from OSAP, no consensus about treatment recom-
mendations exists (3,23). In most patients, primary surgery
was performed with the intent to achieve clear resection
margins if this procedure was deemed compatible with the
preservation of essential organ function and/or quality of
life. A wide resection was defined as no detectable tumor
cells and indifferent tissue between tumor and resection
margin regardless of distance, whereas (focal) marginal
resection was characterized by the presence of reactively
transformed tissue between the tumor and resection margin
of any latitude. Neoadjuvant treatment consisted of che-
motherapy regimens according to EURAMOS-1 (24) or
EURO-B.O.S.S. (EUROpean Bone Over 40 Sarcoma Study)
protocols. Radiotherapy was indicated only in cases with
primarily inoperable disease or local recurrences but not
routinely in combination with surgery, in contrast to the
procedure described in the study by Baumhoer et al. (1).
Immunohistochemistry
We performed immunohistochemistry (IHC) with mouse
monoclonal antibodies against human MAGE-A (clone 6C1,
anti-MAGE-A1, Santa Cruz Biotechnology, Inc., Dallas,
Texas); Mab 57B anti-MAGE-A3 protein, which was kindly
provided by C. Spagnoli, Basel, Switzerland). For represen-
tative images (Figure 1). In fact, most of the known MAGE-A
family members are recognized by clone 6C1 (25), while in
tissue sections, Mab 57B primarily detects MAGE-A4 (26).
Sections (4 mm) of formalin-fixed and paraffin-embedded
tissues were used for IHC analysis. Deparaffinization, anti-
gen retrieval, and blocking of nonspecific binding were
performed according to standard procedures described by
the manufacturer. Tissue sections were incubated overnight
at 4oC with the primary antibody (1:50 dilution of Mab 6C1
and 1:20 dilution of Mab 57B), followed by incubation
with a polyclonal rabbit anti-mouse antibody (1:200, Dako
Denmark A/S, Glostrup, Denmark) and subsequent immu-
nohistochemical reaction with a streptavidin binding system
(Dako Denmark A/S). The peroxidase reaction product was
visualized by AEC+ high substrate chromogen stain (Dako
Denmark A/S). After counterstaining with hematoxylin,
slides were assessed by a pathologist. For each section, three
regions of interest (B450 to 550 cells) were defined, and the
positively stained cells were counted under a microscope
(magnification 20x). Healthy mucosal sections served as
negative controls, and testis tissue served as positive controls
for MAGE expression. Both nuclear and cytoplasmic staining
were regarded as positive for MAGE-A expression. Staining
patterns as well as the intensity of the staining were docu-
mented (0: no staining, 1: slight staining, 2: medium staining,
3: strong staining).
Data Acquisition and Statistical Analysis
The authors reviewed the patient’s individual institutional
charts and directly contacted the Austrian National Register.
Figure 1 - Immunohistochemical staining with MAGE-A Mab 6C1
(Dako). Left column: mucosal sections were used as negative
controls; middle column: testis tissue sections were used as
positive controls; right column: representative sections of OSAJ
tissues; each at 4x, 10x and 20x magnification.
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Data obtained from medical records included patient age,
gender, site, treatment modality, tumor grade and histologi-
cal subtype. Demographic data are presented using the
median, minimum and maximum values unless otherwise
stated. Descriptive statistics were performed to define the
relevant characteristics and their manifestation. A compar-
ison of the proportions for the variables of interest of the
study group versus published data was made using Fisher’s
exact test.
The following potential clinical and histopathological
as well as immunohistochemical prognostic parameters
were collected: presence or absence of metastatic disease
at the time of diagnosis, occurrence of local or metastatic
disease during follow-up, response to neoadjuvant chemo-
therapy, grading, resection margins and MAGE-A expres-
sion. MAGE-A expression was defined as either negative
or positive without defining cut-off levels. Clinical, patho-
logical parameters and MAGE-A expression were corre-
lated with overall survival. Estimates of overall survival
(OS) and disease-specific survival (DSS) and calculation of
survival rates were derived by the Kaplan-Meier method.
The relation between each variable and OSAJ was tested
using the Cox proportional hazard model. The log-rank
test (Mantel-Cox) was used for analysis of the significance
of differences between the DSS rates of this study and
of the DOESAK group (data shown in Table 2). p-values
o0.05 were assumed to denote a statistically significant
difference. Statistical analyses were performed with SPSS
24.0 (SPSS Inc., Chicago, IL, USA).
’ RESULTS
We included 18 patients with OSAJs in this analysis and
compared the results with the largest published datasets
known. These were the results of the DOESAK registry group
(1) and the results based on the SEER tumor database (3).
Demographic data and a descriptive analysis are shown in
Table 1. No significant differences between most of the
characteristics compared were found except for type of the
primary treatment modality and tumor grade. Baumhoer et al.
(1) as well as Lee et al. (3) described a significantly higher
percentage of exclusively surgical procedures for the treatment
of OSAJ as well as a significantly higher incidence for low-
grade OSAJ. The mortality in our study group was 22% (4/18
patients) compared to 28% in the DOESAK registry cohort.
The median follow-up in our collective was 26.0 (range
0.7-144.1) months. Four patients (22%) developed metas-
tases, but only one patient had metastatic disease to the lung
at the time of initial diagnosis. The median time for the
development of metastasis was 14.8 months.
Wide resection margins were achieved in 62.5% of the
operated cases. We did not attempt to further analyze the
potential association of the width of resection margins to
outcome due to the small number of patients in our study.
Furthermore, the presence of close margins has not been
found to be associated with local control in conventional
OSA (27). Focal marginal resection was documented in our
collective in 6 out of 16 (37.5%) operated patients. However,
no attempts were made to further extend the surgery in
any of these patients. Six patients (33%) developed a loco-
regional relapse, three of whom (12.5%) had wide resection.
The median time to locoregional recurrent disease was
6.6 months.
Two of 18 (11.1%) patients who received chemotherapy
without surgery did not achieve a complete response.
Among those patients who received preoperative che-
motherapy, only one of 5 patients showed a partial response
towards chemotherapy.
Kaplan-Meier estimates were calculated for OS and DSS
(Figure 2). The median OS was 117.0 months (SE 16.3; CI
Table 1 - Demographic, tumor and treatment characteristics. Data were compared with data from the DOESAK registry (1) and the
SEER tumor database (3). For comparisons of the means between the groups, Fisher’s test (two-tailed) was used.
Study group
N=18*
N (%)
DOESAK
N=214*
N (%)
p-value SEER
N=541*
N (%)
p-value
Age (years)
Mean (SD) 42 (16) 39 (19) 0.516 41 (21) 0.842
Range 24-80 3-83 0-90
Sex
Female 7 (39) 104 (49) 0.471 271 (50) 0.474
Male 11 (61) 110 (51) 270 (50)
Location
Maxilla 6 (33) 78 (36) 1.000 301 (56) 0.090
Mandible 12 (67) 136 (64) 240 (44)
Surgery N = 201 N = 533
No resection 2 (11) 5 (2) 0.105 79 (16) 1.000
Resection 16 (89) 196 (98) 454 (84)
Tumor grade N = 327
High grade 18 (100) 197 (92) 0.007 221 (68) o0.0001
Low grade 0 (0) 17 (8) 106 (32)
Histological subtype** N = 192 N = 507
Osteoblastic 14 (78) 144 (75) 1.000 372 (73) 1.000
Chondroblastic 3 (17) 31 (16) 102 (20)
Fibroblastic 1 (5) 17 (9) 33 (7)
Primary treatment modality N=16 N=179 N=442
Surgery alone 4 (25) 127 (71) 0.0004 320 (72) 0.0002
Surgery & CHT or RT 12 (75) 52 (29) 122 (28)
*N=18 in the study group; N=214 in the DOESAK and N=541 in the SEER collectives if not indicated otherwise.
**Only the most common high-grade histological subtypes are shown.
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95% 85.0-149.0), and the median DSS was 141.9 months (SE
28.8; CI 95% 85.4-198.4). Four of eighteen patients died of
their disease (3/18 consequently to relapse, 1/18 due to
progression after lack of response to primary chemotherapy).
OS was 85.9% at five years and 34.4% at ten years. DSS was
93.8% after five years and 56.3% after ten years. The two
parameters that were associated with worsened outcome in
our study as well as in the comparator group (the DOESAK
registry) were development of metastasis or relapse and
were significantly associated with survival (Table 2). In our
study group, differences between patients who had metas-
tases or suffered from a recurrence and those without an
event were significant according to the log-rank test (Mantel-
Cox; p-value 0.033 and 0.037, respectively). Neither previous
irradiation nor the presence of benign lesions, both known
risk factors for OSA development (28), were associated with
DSS (p=0.083). MAGE-A expression was detected in 28% of
the OSAJ patients (5/18). Neoadjuvant chemotherapy did
not affect MAGE-A expression (4/18), and no significant
association of MAGE-A expression with survival was found
(p=0.569).
Univariate analysis using the Cox proportional hazard
model revealed no further significant risk factors (data not
shown). As a consequence, we did not include additional
putative prognostic variables in the multivariate model.
’ DISCUSSION
Here, we describe for the first time the institutional
results of two decades of treatment for OSAJ. As mentioned
above, OSAJ is a rare disease. Different treatment approaches
and diverse treatment modalities, as well as other factors,
therefore characterize the current state of treatment for this
type of sarcoma. In this study, we present a retrospectively
analyzed group of patients with OSAJs treated at a single
institute and compared our data with the two largest pub-
lished datasets of OSAJs (1,3). In rare cases, an OSA may also
be induced secondarily after radiation therapy. Most of the
knowledge concerning radiation-induced OSAJs is derived
from case reports (4,5). We identified two cases of potentially
induced sarcoma in our collective, and we have provided
preliminary evidence for a worsened prognosis of these
tumors. We also investigated the potential role of MAGE-A
expression as a prognostic marker.
As OSAJ is primarily considered a localized disease,
radical resection is the preferred treatment modality (8,29).
Surgery was performed in 90% of our patients, a frequency
similar (97%) to that reported in the DOESAK collective (1),
as well as to the percentage of operations (81.6%) reported by
Lee et al. (3). In the retrospective cohort analysis of the SEER
cancer registry conducted by Lee et al. (3), 59% of the patients
were operated, and 22.6% of the patients had surgery plus
radiation therapy, while in 10.7% of the cases, no treatment
was performed. In our study, no surgery was performed in
11% of OSAJ patients because of the presence of unresectable
tumors at the time of diagnosis. In the collective published by
Baumhoer et al. (1), 2.3% of OSAJ cases were reported to be
unresectable.
DSS after 10 years in our study group (56%) was com-
parable to the DSS in the DOESAK registry group (59% (1))
as well as in the SEER database cohort (54% (3)). The median
OS in the present study (10 months) was similar to the OS
(8 months) described by Lee et al. (3). Unfortunately, Lee et al.
(3) did not provide information about the impact of surgery
alone on DSS, although surgery was the only significant
parameter of the study collective that affected survival when
Figure 2 - Kaplan-Meier curves for OSAJ OS and DSS rates of the
study collective.
Table 2 - Study group versus the DOESAK registry group (1). Five- and 10-year disease-specific survival rates (%) according to different
variables.
Parameter Subgroup Study group DOESAK registry group
5 y 10 y PLR-test 5 y 10 y PLR-test
Gender Male 87.5 43.8 0.164 66.5 61.0 0.961
Female 83.3 0 66.9 56.5
Origin Mandible 90.9 68.2 0.751 66.8 59.9 0.811
Maxilla 100 0 66.6 58.7
Tumor grade Low na na na 100 100 0.027
High 93.8 56.3 64.6 56.7
Histological subtype Osteoblastic 88.9 29.6 0.240 63.8 58.0 0.096
Chondroblastic 0 0 75.7 63.1
Metastases No 100 na 0.033 78.3 74.1 o0.001
Yes 80.0 26.7 19.7 7.9
Recurrence No 100 60.0 0.037 83.2 83.2 o0.001
Yes 66.7 na 51.9 48.7
na: not available.
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compared to the DOESAK registry (1) and the SEER tumor
database (3). Lee et al. (3) did not report on the incidence of
recurrence, and they did not provide follow-up data or results
about the incidence or rate of metastasis in their analysis.
When comparing our 5-year and 10-year DSS data with those
of Baumhoer et al. (1) (Table 2), metastatic and recurrent
disease also significantly influenced DSS (p-values 0.033 and
0.037). In our study, the combination of surgery with chemo-
therapy had no significant impact on DSS (p=0.619), and no
significant association was found between MAGE-A expres-
sion and DSS (p=0.569).
Most OSAJs were high-grade tumors of the osteoblastic
subtype (78%), similar to the incidence reported (75%) in the
DOESAK registry (1) and the study (73%) by Lee et al. (3).
Seventeen percent of the high-grade tumors had a chondro-
blastic subtype, compared to 16% (1) and 20% (3) in the
comparative datasets. The third most frequent subtype, the
fibroblastic subtype, showed a similar prevalence in the three
analyzed collectives (present study: 5%, DOESAK: 9% (1),
SEER: 7% (3)). We found a tendency in our collective towards
a more frequent application of adjuvant chemotherapy (39%
in our collective versus 14% in the DOESAK registry group
(1)). No comparison was possible with the data from Lee et al.
(3), who did not provide any information about chemother-
apy in combination with surgery. However, the addition of
chemotherapy was not associated with an improvement in
the time to development of metastasis (median 23.8 months
with chemotherapy versus 26 months without chemotherapy).
A local recurrence rate of 33% in our collective was similar
to the percentage (44%) reported by Baumhoer et al. (1). The
average time to local recurrence in the DOESAK registry
cohort (1) was 22.5 months, which is comparable to the mean
time to relapse of 18.17 months in the study collective.
Radiation-induced OSAs are considered highly aggressive
lesions with local recurrence rates of up to 86% in com-
parison to 22% of primary OSAs of the head and neck
(30,31). Although radiation-induced OSAs are not explicitly
reported in the study by Baumhoer et al. (1), we identified
two patients who had previous radiotherapy more than
15 years before the occurrence of the sarcoma. One patient
was treated for a benign lesion of the ethmoid sinus with a
total dose of 53 Gy, and one patient was irradiated for a naso-
pharyngeal squamous cell carcinoma with a total dose of
70 Gy. The other two patients with risk factors had fibrous
dysplasia in their medical history (32,33).
We hypothesized that the majority of OSAJ patients would
be MAGE-A negative, as OSAJs are described in the litera-
ture to be more ‘‘benign’’ than OSAPs are. Indeed, we found
no statistically significant association of MAGE-A expression
with survival.
This study has some obvious limitations, such as its small
number of patients and its retrospective nature, and conclu-
sions based on these data have to be taken with caution.
However, our collective, with respect to some fundamental
basic characteristics, such as age distribution, outcome data,
and histology, seems to represent quite well the patient
collectives from other institutions. Our study collective has
similar demographics as well as tumor-associated character-
istics compared to those of the two reference groups, except
for the utilization of the treatment modalities (Tables 1 and 2).
The age distribution (mean 42 years) of the presented patient
cohort resembled the expected distribution (mean of 39 years
in the DOESAK registry (1)) and the published mean of
41 years in the literature (3,34). In two-thirds of the patients,
the mandible was the primary affected site. A similar prefe-
rence for the mandible as the primary site of occurrence was
reported in the study by Baumhoer et al. (1), while Lee et al.
(3) described a 50% prevalence for the lower jaw. In contrast
to our study, neither Lee et al. (3) nor Baumhoer et al. (1)
differentiated between maxillary OSAJs and craniofacial
OSAs, which are known to show a significantly worse pro-
gnosis (9,35).
Lee et al. (3) mentioned several limitations of the SEER
database, such as the ambiguous anatomical assignment of
tumors to the maxilla or other craniofacial sites. Additionally,
the majority of OSAJs that were classified as ‘‘not otherwise
specified’’ (NOS) were automatically regarded as tumors of
the osteoblastic subtype. In our view, because of such uncer-
tainties in large databases, single-institutional reports, despite
small patient numbers, may have some distinct advantages.
In conclusion, prospective studies of OSAJs are only
feasible in a multicenter study setting and need to be con-
ducted over prolonged time periods. Therefore, uncertain-
ties about the optimal treatment strategies will most likely
remain as factors that may affect the outcome of OSAJ patients
and are reported differently in the literature (1,3,36).
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